Adriamycin
Primary Central Nervous System Lymphoma
Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Juan P. Alderuccio, MD
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06730542CT.gov Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma | — | Recruiting | — | — | — |
NCT06901999CT.gov Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients | — | Not Yet Recruiting | — | — | — |
NCT05256641CT.gov Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT05518383CT.gov B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | — | Recruiting | — | — | — |
NCT04906902CT.gov Acalabrutinib in CNSL | — | Active Not Recruiting | — | — | — |
NCT04462328CT.gov Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04548648CT.gov A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas | — | Active Not Recruiting | — | — | — |
NCT03964090CT.gov Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) | — | Active Not Recruiting | — | — | — |
NCT02203526CT.gov Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01848652CT.gov Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine. | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Central Nervous System Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | Juan P. Alderuccio, MD | Approved | BB · 70 |
| Etoposide | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P4 | BBB |
| (+)-Vincristine | Ono Pharmaceutical Co., Ltd. | P4 | BBB |
| Methotrexate | Assistance Publique Hopitaux De Marseille | P4 | BB |
| Idarubicin | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P4 | BB |
| Orelabrutinib | The First Affiliated Hospital with Nanjing Medical University | P3 | BB |
| Cyclophosphamide | Juan P. Alderuccio, MD | P4 | BB |
| Cytarabine | The Lymphoma Academic Research Organisation | P4 | BB |
| Rituximab | Ono Pharmaceutical Co., Ltd. | P4 | BB |
+42 more in the Primary Central Nervous System Lymphoma cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Adriamycin in Primary Central Nervous System Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/adriamycin-primary-central-nervous-system-lymphoma-102375
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →